NCT03476798View on ClinicalTrials.gov

Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

June 29, 2018

Primary Completion Date

May 12, 2020

Study Completion Date

September 29, 2023

Conditions
Cervical CancerEndometrial Cancer
Interventions
DRUG

Rucaparib

Rucaparib 600mg PO BID daily

DRUG

Bevacizumab

Bevacizumab 15mg/kg IV on day 1 of each cycle

Trial Locations (3)

22903

University of Virginia Cancer Center, Charlottesville

55455

University of Minnesota, Minneapolis

73117

Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City

Sponsors

Collaborators (1)

Clovis Oncology, Inc.
All Listed Sponsors
collaborator

Clovis Oncology, Inc.

INDUSTRY

lead

University of Oklahoma

OTHER

NCT03476798 - Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium | Biotech Hunter | Biotech Hunter